IDEAS home Printed from https://ideas.repec.org/a/eso/journl/v45y2014i2p245-259.html
   My bibliography  Save this article

Financing Sustainable Drug Development for Neglected Diseases: A Case of Push-Pull Mechanisms and Global Public Goods

Author

Listed:
  • Jimmy Le

    (Paris School of International Affairs (PSIA), Sciences Po, Paris)

Abstract

Neglected tropical diseases (NTDs) often afflict the poorest populations of the world. This observation suggests that while demands for new drugs against NTDs continue to grow, there is still a low profit margin for any innovation produced. As a result, there are few incentives for private industrial investments in drugs R&D for neglected diseases, and thus, urgent need for a new set of mechanisms to drive research towards these often 'forgotten' issues. One possible solution comes in the form of a collaborative partnership where drugs for neglected disease are seen by public, private and philanthropic organs as global public goods. In this scenario, multilateral collective action creates an artificial market where there are fewer risks for innovators and more results for benefactors. Coupled with policy-based push-pull mechanisms, these collaborations, like the Drugs for Neglected Diseases Initiative (DNDi), mitigate the challenges of a failed market and represents a paradigm for other potential sustainable development collaborations, post-2015.

Suggested Citation

  • Jimmy Le, 2014. "Financing Sustainable Drug Development for Neglected Diseases: A Case of Push-Pull Mechanisms and Global Public Goods," The Economic and Social Review, Economic and Social Studies, vol. 45(2), pages 245-259.
    • Handle: RePEc:eso:journl:v:45:y:2014:i:2:p:245-259
    as

    Download full text from publisher

    File URL: https://www.esr.ie/article/view/139/85
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Bernard Pécoul, 2004. "New Drugs for Neglected Diseases: From Pipeline to Patients," PLOS Medicine, Public Library of Science, vol. 1(1), pages 1-1, October.
    2. Suerie Moon & Jorge Bermudez & Ellen 't Hoen, 2012. "Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?," PLOS Medicine, Public Library of Science, vol. 9(5), pages 1-5, May.
    3. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
    4. Toole, Andrew A., 2011. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers 11-063, ZEW - Leibniz Centre for European Economic Research.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Aerts, Céline & Sunyoto, Temmy & Tediosi, Fabrizio & Sicuri, Elisa, 2017. "Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature," Health Policy, Elsevier, vol. 121(7), pages 745-754.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Toole, Andrew A. & King, John L., 2011. "Industry-science connections in agriculture: Do public science collaborations and knowledge flows contribute to firm-level agricultural research productivity?," ZEW Discussion Papers 11-064, ZEW - Leibniz Centre for European Economic Research.
    2. Daniel Tobias Michaeli & Thomas Michaeli & Sebastian Albers & Tobias Boch & Julia Caroline Michaeli, 2024. "Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 979-997, August.
    3. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
    4. Paul Oldham & Stephen Hall & Oscar Forero, 2013. "Biological Diversity in the Patent System," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-16, November.
    5. Pies, Ingo & Hielscher, Stefan, 2007. "Das Problem der internationalen Arzneimittelversorgung: Eine wirtschaftsethische Perspektive," Discussion Papers 2007-1, Martin Luther University of Halle-Wittenberg, Chair of Economic Ethics.
    6. Sandeep P Kishore & Gloria Tavera & Peter J Hotez, 2010. "The Global Health Crisis and Our Nation's Research Universities," PLOS Neglected Tropical Diseases, Public Library of Science, vol. 4(2), pages 1-3, February.
    7. Mathies, Charles & Slaughter, Sheila, 2013. "University trustees as channels between academe and industry: Toward an understanding of the executive science network," Research Policy, Elsevier, vol. 42(6), pages 1286-1300.
    8. Shiri Mermelstein & Hilde Stevens, 2022. "TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines," ULB Institutional Repository 2013/337220, ULB -- Universite Libre de Bruxelles.
    9. Rutger P. Daems PhD & Edith L. Maes DBA & Guy Nuyts, PhD, 2013. "Advancing Pharmaceutical R&D on Neglected Diseases: Valuing Push and Pull Economic Incentive Mechanisms," Working Papers 2013/11, Maastricht School of Management.
    10. John Liechty & Stefan Wuyts, 2021. "'If I had a hedge fund, I would cure diabetes': endogenous mechanisms for creating public goods," SN Business & Economics, Springer, vol. 1(10), pages 1-18, October.
    11. Ria Christine Siagian & Dumilah Ayuningtyas, 2019. "Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-13, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eso:journl:v:45:y:2014:i:2:p:245-259. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Aedin Doris (email available below). General contact details of provider: https://www.esr.ie .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.